Monika Bujak

Monika Bujak

Auto-generated profile, based on publicly available information

Monika Bujak

Medical University of Silesia in Katowice, Katowice, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
RNRafał Niemiec
Rafał Niemiec
MNMalgorzata Niemiec
Malgorzata Niemiec
MNMartyna Nowak
Martyna Nowak
BGBarbara Gurba
Barbara Gurba
MBMonika Bujak
Monika Bujak
Katarzyna Mizia-StecKatarzyna Mizia-Stec
Katarzyna Mizia-Stec
Background/Objectives: Angiotensin receptor–neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction, the advantage of ARNI has not been clearly proven. The efficacy of ARNI is compared with that of ACEI/ARB therapy in patients with their first AMI in terms of improvement of post-infarction LV systolic function. Methods: The study was conducted as a retrospective one-center cross-sectional analysis. Overall, 1473 pts (990 M, median age 71 [64; 77]) with AMI (their first AMI, complete coronary revascularization, no prior coronary revascularization or history of HF) hospitalized in 2022–2024 were enrolled in a retrospective cross-sectional analysis. The study population was categorized into pts receiving ARNI and ACEI/ARB. Then, based on the ARNI subgroup, matching that included age, sex, and LV ejection fraction (LVEF) was performed by using the 1:1 nearest neighbor method without returning. Finally, two groups (ARNI vs. ACEI/ARB) of 30 pts were obtained and analyzed at baseline and at a 6-week follow-up. The improvement of post-infarction LV systolic function was obtained in terms of LVEF, ΔLVEF, and relative ΔLVEF values (ΔLVEF/baseline LVEF). Results: The comparison of baseline characteristics revealed borderline lower initial LVEF (30 vs. 36%, p = 0.076) and a higher frequency of SGLT-2 inhibitor use (70% vs. 36.7%, p = 0.01) in the ARNI subgroup. At the 6-week follow-up, in both subgroups, a significant improvement in the median LVEF values was achieved—from a median LVEF value of 30% (27.3; 38) to 37% (30; 43; p = 0.0008) in the ARNI subgroup and from a median LVEF value of 36% (33; 39) to 45% (42; 52; p < 0.0001) in the ACEI/ARB subgroup. The median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p = 0.018]. Similarly, the median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p = 0.047]. The vast majority of patients, particularly in the ARNI group (99.7%), were treated with the lowest available dose of the drug. Conclusions: Our current experience in ARNI therapy after AMI is promising; however, it is limited to a small group of patients with severe impairment of LV systolic function. Regardless of the significant improvement in the baseline LVEF observed in patients receiving both ACEI/ARB and ARNI at the 6-week follow-up, the absolute and relative increases in the LVEF were higher in subjects treated with ACEI/ARB. However, the clinical benefits of ARNI therapy may emerge more gradually, and its advantages could become more apparent over a longer follow-up period. The clinical efficacy of early use of ARNI in the setting of AMI needs further evaluation.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAnna Szot
Anna Szot
JSJędrzej Sztajura
Jędrzej Sztajura
MBMonika Bujak
Monika Bujak
KCKatarzyna Helena Chowaniec-Rybka
Katarzyna Helena Chowaniec-Rybka
Introduction and Purpose: After cardiovascular diseases, malignant tumors are the second most common cause of death, disability, and reduced quality of life. Cancer-related cognitive impairment (CRCI) encompasses transient or persistent cognitive dysfunction, either subjectively reported by patients or objectively confirmed through neuropsychological testing. The aim of this study is to discuss the current state of knowledge and research on the impact of non-pharmacological interventions, especially the impact of various forms of physical activity (aerobic, strength, mixed) on the cognitive functions of cancer patients during and after treatment. Materials and Methods: A comprehensive literature search was conducted using the PubMed, BioMed Central, Scopus, and Google Scholar databases. Keywords included: physical activity, cognitive function, cancer survivors, quality of life, chemotherapy, and cancer-related cognitive impairment. References cited within selected articles were also reviewed. Studies from the past 10 years were analyzed, applying carefully defined inclusion and exclusion criteria. This review presents the latest clinical evidence and current strategies for the management of cancer-related cognitive impairment. Conclusions: CRCI is a prevalent condition among cancer patients, significantly impacting their quality of life and overall well-being. Cognitive dysfunction may arise from various cancer therapies, not solely chemotherapy. The findings underscore the need for systematic monitoring of cognitive function in oncology patients, along with the integration of preventive and rehabilitative measures into comprehensive care plans. Early detection of CRCI and the implementation of cognitive rehabilitation and physical activity interventions are crucial for improving patient outcomes.

14 February 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
KCKatarzyna Helena Chowaniec-Rybka
Katarzyna Helena Chowaniec-Rybka
MBMonika Bujak
Monika Bujak
JSJędrzej Sztajura
Jędrzej Sztajura
ASAnna Szot
Anna Szot
INTRODUCTION AND PURPOSE Musculoskeletal injuries, including ligament ruptures, sprains, partial tears, muscle damage, and fractures, are among the most common injuries observed in athletes. Properly conducted rehabilitation is based on early and appropriate patient mobilization following trauma, aiming to restore mobility and strength of the affected musculoskeletal structures during convalescence. Effective management of post-traumatic pain remains a crucial component of therapy, as pain reduction facilitates early mobilization and return to pre-injury functional status. The aim of this study was to review rehabilitation approaches used after various musculoskeletal injuries sustained during sports activity. MATERIALS AND METHODS Literature contained in PubMed and BioMed Central databases was searched using keywords such as rehabilitation, sport, musculoskeletal injuries, physical activity, pain management, exercise, therapy. Referenced sources in selected publications and thematic textbooks were also utilized. CONCLUSIONS Musculoskeletal injuries may result in significant functional limitations; however, their negative consequences can be effectively minimized through the timely initiation of structured rehabilitation. Exercises should be introduced gradually and adjusted to the injury stage to avoid excessive load on healing tissues. Adequate pain management is essential to support early mobilization and optimize recovery outcomes in athletes.

8 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RNRafał Niemiec
Rafał Niemiec
MNMalgorzata Niemiec
Malgorzata Niemiec
MNMartyna Nowak
Martyna Nowak
BGBarbara Gurba
Barbara Gurba
MBMonika Bujak
Monika Bujak
Katarzyna Mizia-StecKatarzyna Mizia-Stec
Katarzyna Mizia-Stec
Background/Objectives: Angiotensin receptor-neprilysin inhibitor (AR-NI) has a well-established advantage over angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute myocardial infarction (AMI) with left ventricular (LV) systolic dysfunction the advantage of ARNI has not been clearly proven. To com-pare of the efficacy of ARNI versus ACEI/ARB therapy in patients with the first AMI in terms of improvement of post-infarction LV systolic function. Methods: Overall 1473 pts (990M, median age 71 [64;77]) with AMI (the first AMI, complete coronary revascularization, no prior: coronary revas-cularization, history of HF) hospitalized in 2022-2024 were enrolled into retrospective cross-sectional analysis. The study population was catego-rized into pts receiving ARNI and ACEI/ARB. Then based on ARNI subgroup included age, sex, and LV ejection fraction (LVEF) matching was performed by using the 1:1 nearest neighbour method without returning. Finally two groups (ARNI vs ACEI/ARB) of 30 pts were obtained and an-alysed at baseline and in 6-week follow-up. The improvement of post-infarction LV systolic function was obtained as LVEF value, ΔLVEF and relative ΔLVEF (ΔLVEF / baseline LVEF). Results: The comparison of baseline characteristics revealed borderline lower initial LVEF (30 vs 36%, p=0.076) and higher frequency of of SGLT-2 inhibitors use (70% vs 36.7%, p=0.01) in the ARNI subgroup. In 6-week follow-up in both subgroups a significant improvement in the median LVEF values was achieved: from median LVEF value 30% (27.3; 38) up to 37% (30; 43; p=0.0008) in ARNI and from median LVEF value 36% (33; 39) up to 45% (42; 52; p<0.0001) in ACEI/ARB subgroup. Median ΔLVEF in the ACEI/ARB subgroup was higher [10% (6; 12)] than in the ARNI subgroup [6% (2; 10.25), p=0.018]. Similarly median relative ΔLVEF was higher in the ACEI/ARB subgroup [30% (15.4; 40)] than in the ARNI group [17.5% (7; 31.9), p=0.047]. Conclusions: Our current experience in ARNI therapy after AMI is promising, however, it is limited to a small group of patients with severe impairment of LV systolic function. Regardless of significant improvement of baseline LVEF observed in patients receiving both ACEI/ARB and ARNI in 6 week follow-up the value of absolute and relative LVEF increase were higher in subjects treated with ACEI/ARB. The clinical efficacy of early use of ARNI in the setting of AMI needs further evaluation.